XML 28 R15.htm IDEA: XBRL DOCUMENT
v3.25.4

Earnings Per Share | 12 Months Ended
--- | ---
Dec. 31, 2025
Earnings Per Share [Abstract] |
Earnings Per Share | 4. Earnings Per Share The following table sets forth the computation of basic and diluted (loss) earnings per share for the years ended December 31, 2025, 2024 and 2023 (in thousands, except per share amounts):
|  | Year Ended December 31, |
|  | 2025 |  |  | 2024 |  |  | 2023 |
Numerator: |  |  |  |  |  |  |  |  |
Net (loss) income attributable to Acadia Healthcare Company, Inc. |  | $ | (1,102,772 | ) |  | $ | 255,612 |  |  | $ | (21,667 | )
Denominator: |  |  |  |  |  |  |  |  |
Weighted-average shares outstanding for basic earnings per share |  |  | 90,705 |  |  |  | 91,621 |  |  |  | 90,949 |
Effects of dilutive instruments |  |  | — |  |  |  | 438 |  |  |  | — |
Shares used in computing diluted earnings per common share |  |  | 90,705 |  |  |  | 92,059 |  |  |  | 90,949 |
(Loss) earnings per share attributable to Acadia Healthcare Company, Inc. stockholders: |  |  |  |  |  |  |  |  |
Basic |  | $ | (12.16 | ) |  | $ | 2.79 |  |  | $ | (0.24 | )
Diluted |  | $ | (12.16 | ) |  | $ | 2.78 |  |  | $ | (0.24 | )
For the years ended December 31, 2025 and 2023, respectively, approximately 0.6 million and 0.9 million outstanding shares of restricted stock and shares of common stock issuable upon exercise of outstanding stock option awards have been excluded from the calculation of dilutive weighted-average shares outstanding. These shares are excluded from the calculation of diluted earnings per share in the consolidated statement of operations because the net loss for the years ended December 31, 2025 and 2023 causes such securities to be anti-dilutive. Approximately 1.0 million, 0.7 million and 0.3 million shares of restricted stock and common stock issuable upon exercise of outstanding stock options were excluded from the calculation of diluted earnings per share for the years ended December 31, 2025, 2024 and 2023, respectively, because their effect would have been anti-dilutive.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration